Axsome Therapeutics, Inc. (LON: 0HKF)

Market Cap	4.02B
Revenue (ttm)	252.52M
Net Income (ttm)	-232.00M
Shares Out	n/a
EPS (ttm)	-4.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,758
Average Volume	1,480
Open	96.19
Previous Close	94.23
Day's Range	95.50 - 101.66
52-Week Range	55.64 - 101.66
Beta	n/a
RSI	59.85
Earnings Date	Feb 20, 2025

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 545
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKF

Financial Performance

In 2023, Axsome Therapeutics's revenue was $270.60 million, an increase of 440.80% compared to the previous year's $50.04 million. Losses were -$239.24 million, 27.8% more than in 2022.

Financial numbers in USD